We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France.
- Authors
Marissal, Jean-Pierre; Selke, Bernard
- Abstract
To assess the cost effectiveness of aspirin 25 mg plus dipyridamole 200 mg twice daily in the secondary prevention of ischaemic stroke, according to the French social security perspective, using efficacy data from the second European Stroke Prevention Study (ESPS-2). The ESPS-2 was a double-blind, placebo-controlled clinical trial which assessed the efficacy of four secondary prevention strategies: (i) placebo; (ii) aspirin (acetylsalicylic acid) 25 mg twice daily; (iii) dipyridamole 200 mg twice daily; and (iv) aspirin 25 mg plus dipyridamole 200 mg twice daily.
- Publication
PharmacoEconomics, 2004, Vol 22, Issue 10, p661
- ISSN
1170-7690
- Publication type
Journal Article
- DOI
10.2165/00019053-200422100-00004